Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines

Executive Summary

Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.

You may also be interested in...



Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years

Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.

Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.

MSF Attacks Vaccines Collaboration Over ‘Toothless’ New Equitable Access Policy

The Coalition for Epidemic Preparedness Innovationhas come under attack from Médecins sans Frontières over its revised equitable vaccines access policy, which the NGO claims has been watered down at the behest of the pharmaceutical industry.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel